Artesunate for cytomegalovirus infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Feb 2025: Trial registered, NCT06853184
  2. 1 Aug 2025: Trial started, NCT06853184

The trials

NCT06853184: Study Evaluating the Efficacy and Safety of Artesunate

State
Under way
Phase
Phase 2
People
90 planned
Started
1 Aug 2025
Primary completion
31 May 2028
Arms
Low Dose Artesunate, High Dose Artesunate
Results
None posted
  1. 28 Feb 2025: Trial registered
  2. 1 Aug 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Arsumax, Plasmotrin, Zysunate.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.